⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1311493 | 0.80 | — | — | |
| SCHEMBL1309635 | 0.80 | — | — | |
| SCHEMBL79539 | 0.79 | — | — | |
| SCHEMBL30295390 | 0.79 | ALOX5 (0.47) | — | |
| Formaldehyde SCHEMBL28362816 | 0.78 | ALOX5 (0.47) | — | |
| SCHEMBL1310355 | 0.75 | — | — | |
| SCHEMBL5002209 | 0.75 | — | — | |
| SCHEMBL19718394 | 0.75 | — | — | |
| SCHEMBL18827337 | 0.75 | ALOX5 (0.44) | — | |
| SCHEMBL15854170 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0649412-B1 | PHARMACEUTICAL PYRIDINE COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2003-01-15 | — | — | EP | claimed |
| US-5643914-A | Pharmaceutical pyridine compounds | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-01 | — | — | US | claimed |
| EP-0732919-A4 | DIPHENYL-2-PROPENOATES AND HOMOLOGS THEREOF USEFUL FOR TREATING DISEASES ASSOCIATED WITH LEUKOTRIENE B4 | SMITHKLINE BEECHAM CORP (US) | 1997-05-02 | — | — | EP | claimed |
| US-5569677-A | TREATING PSORIASIS AND INFLAMMATORY BOWEL DISEASE | SMITHKLINE BEECHAM CORPORATION (US) | 1996-10-29 | — | — | US | claimed |
| EP-0732919-A1 | DIPHENYL-2-PROPENOATES AND HOMOLOGS THEREOF USEFUL FOR TREATING DISEASES ASSOCIATED WITH LEUKOTRIENE B4 | SMITHKLINE BEECHAM CORPORATION (US) | 1996-09-25 | — | — | EP | claimed |
| WO-1995015752-A1 | DIPHENYL-2-PROPENOATES AND HOMOLOGS THEREOF USEFUL FOR TREATING DISEASES ASSOCIATED WITH LEUKOTRIENE B4 | SMITHKLINE BEECHAM CORPORATION (US) | 1995-06-15 | — | — | WO | claimed |
| US-10308610-B2 | Inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-06-04 | — | — | US | disclosed |
| US-20180099936-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-04-12 | — | — | US | disclosed |
| US-9856220-B2 | Inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-01-02 | — | — | US | disclosed |
| US-20160318871-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC. | 2016-11-03 | — | — | US | disclosed |
| US-20130116229-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-8163770-B2 | Benzoxathiin derivative | MSD. K. K. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-7960394-B2 | 3,8-dimethyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]-4(3H)-quinazolinone; 6-chloro-3-methyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]pyrido[3,4-d]-pyrimidin-4(3H)-one; 2-[4-(1-cyclopentyl-4-piperidinyloxy)phenyl]-3-methylpyrido[2,3-d]-pyrimidin-4(3H)-one; treats metabolic, nervous system, vascular disorders | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20100168156-A1 | Novel Benzoxathiine Derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
| EP-2185570-A2 | NOVEL ACTIVATORS OF GLUCOKINASE | Metabasis Therapeutics, Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009023718-A2 | NOVEL ACTIVATORS OF GLUCOKINASE | METABASIS THERAPEUTICS, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
| US-20080275069-A1 | Quinazoline Derivative | MSD K.K. (JP) | 2008-11-06 | — | — | US | disclosed |
| EP-1944301-A1 | NOVEL BENZOXATHIIN DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-07-16 | — | — | EP | disclosed |
| EP-1757594-A1 | QUINAZOLINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |